


**Product Name** : KRCA-0008  
**Cat. No.** : PC-42979  
**CAS No.** : 1472795-20-2  
**Molecular Formula** : C<sub>30</sub>H<sub>37</sub>ClN<sub>8</sub>O<sub>4</sub>  
**Molecular Weight** : 609.119  
**Target** : Anaplastic Lymphoma Kinase (ALK)  
**Solubility** : 10 mM in DMSO



### Biological Activity

KRCA-0008 is a potent, selective ALK inhibitor with IC<sub>50</sub> of 12 nM (wt ALK), also is potent against various ALK mutants, including L1196M, F1174L, R1275Q, and C1156Y (IC<sub>50</sub>=5-75 nM).

KRCA-0008 weakly inhibits IR (IC<sub>50</sub>=210 nM), inhibits H3122 and BaF3 EML4-ALK L1196M cell proliferation with IC<sub>50</sub> of 80 and 68 nM, respectively.

KRCA-0008 demonstrates in vivo efficacy comparable to Crizotinib in xenograft mice model, has drug-like properties without hERG concerns.

### References

Park CH, et al. *Bioorg Med Chem Lett*. 2013 Nov 15;23(22):6192-6.

Kang CH, et al. *Biochem Biophys Res Commun*. 2015 Aug 28;464(3):762-7.

Lee HJ, et al. *Arch Pharm Res*. 2014;37(9):1130-8.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com